MedReleaf (TSE:LEAF) had its price target upped by Canaccord Genuity from C$21.50 to C$30.00 in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price target would suggest a potential upside of 41.91% from the stock’s current price.
Several other analysts also recently commented on the company. Cowen increased their price objective on MedReleaf from C$20.00 to C$36.00 in a research note on Monday, January 8th. Eight Capital increased their price objective on MedReleaf from C$13.00 to C$20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th.
Shares of MedReleaf (TSE LEAF) traded up C$1.39 during trading on Wednesday, hitting C$21.14. The stock had a trading volume of 649,906 shares, compared to its average volume of 1,013,119. The stock has a market capitalization of $1,970.00 and a P/E ratio of 1,053.50. MedReleaf has a 12-month low of C$6.81 and a 12-month high of C$31.25.
MedReleaf Company Profile
MedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.
Receive News & Ratings for MedReleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedReleaf and related companies with MarketBeat.com's FREE daily email newsletter.